Abstract
In current medical practice, innovators, drug and device companies often debut new interventions before they have shown benefit in robust clinical trials. Practitioners readily use these new therapies, in many cases because the practice is financially rewarding and the intervention makes sense within practitioners’ scientific worldview. Oftentimes, years after a practice was introduced, the medical community puts it to the test in large, well done randomized trials. Empirical evidence suggests that when this happens, nearly half of those practices are contradicted. We call this phenomenon ‘medical reversal’. What are the implications of reversal on our current system of hasty adoption and widespread use of new therapies? Here, we outline the concept of burden of proof in medicine. In the era of evidence-based medicine, who has the burden of proof to show that a therapy works? Currently in clinical practice, innovators and manufacturers are not carrying the burden. Instead, third parties and brave researchers are often required to challenge medical standards years after their introduction. Here, we argue that such a system is untenable. The burden of proof to show that an intervention works must be held by those who develop a new therapy, and by practitioners who profit from the therapy before it is introduced. Here, we promote this as a new physician ethic.
Similar content being viewed by others
References
Alderman, L. (2010) Caring for hips and knees to avoid artificial joints. The New York Times, 23 April.
Angelos, P. (2007) Sham surgery in clinical trials. Journal of the American Medical Association 297 (14): 1545–1546.
Aronow, W.S. (2003) Might losartan reduce sudden cardiac death in diabetic patients with hypertension? The Lancet 362 (9384): 591–592.
Baker, C.B., Johnsrud, M.T., Crismon, M.L., Rosenheck, R.A. and Woods, S.W. (2003) Quantitative analysis of sponsorship bias in economic studies of antidepressants. British Journal of Psychiatry 183 (6): 498–506.
Bang, L.E. et al (2007) Losartan versus atenolol on 24-hour ambulatory blood pressure: A LIFE substudy. Blood Pressure 16 (6): 392–397.
Bar-Eli, M., Azar, O.H., Ritov, I., Keidar-Levin, Y. and Schein, G. (2007) Action bias among elite soccer goalkeepers: The case of penalty kicks. Journal of Economic Psychology 28 (5): 606–621.
Bell, C.M. et al (2006) Bias in published cost effectiveness studies: Systematic review. British Medical Journal 332 (7543): 699–703.
Boden, W.E. et al (2007) COURAGE Trial Research Group: Optimal medical therapy with or without PCI for stable coronary disease. New England Journal of Medicine 356 (15): 1503–1516.
Buchbinder, R. et al (2009) A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. New England Journal of Medicine 361 (6): 557–568.
Carlberg, B., Samuelsson, O. and Lindholm, L. (2004) Atenolol in hypertension: Is it a wise choice? The Lancet 364 (9446): 1684–1689.
Clarke, M. et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. The Lancet 366 (9503): 2087–2106.
Cobb, L.A., Thomas, G.I., Dillard, D.H., Merendino, K.A. and Bruce, R.A. (1959) An evaluation of internal-mammary-artery ligation by a double-blind technic. New England Journal of Medicine 260 (22): 1115–1118.
Cunningham, M.R. et al (2007) Industry-funded positive studies not associated with better design or larger size. Clinical Orthopaedics and Related Research 457 (51): 235–241.
Dahlöf, B., Devereux, R.B. and Kjeldsen, S.E. et al (2002) Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. The Lancet 359 (9311): 995–1003.
DeAngelis, C.D. and Fontanarosa, P.B. (2010) Ensuring integrity in industry-sponsored research primum non nocere, revisited. Journal of the American Medical Association 303 (12): 1196–1198.
Deyo, R.A. et al (2010) Trends, major medical complications, and charges associated with surgery for lumbar spinal stenosis in older adults. Journal of the American Medical Association 303 (13): 1259–1265.
Early Breast Cancer Trialists’ Collaborative Group. (2000) Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomised trials. The Lancet 355 (9217): 1757–1770.
Elliott, C. (2010) White Coat Black Hat: Adventures on the Dark Side of Medicine. Boston, MA: Beacon Press.
Elshaug, A.G. and Garber, A.M. (2011) How CER could pay for itself: Insights from vertebral fracture treatments. New England Journal of Medicine 364 (15): 1390–1393.
Evidence-based Medicine Working Group. (1992) Evidence-based medicine: A new approach to teaching the practice of medicine. Journal of the American Medical Association 268 (17): 2420–2425.
Fall, K. et al (2009) Immediate risk for cardiovascular events and suicide following a prostate cancer diagnosis: Prospective cohort study. PLoS Medicine 6 (12): e1000197.
Friedberg, M., Saffran, B., Stinson, T.J., Nelson, W. and Bennett, C.L. (1999) Evaluation of conflict of interest in economic analyses of new drugs used in oncology. Journal of the American Medical Association 282 (15): 1453–1457.
Gray, D.T., Hollingworth, W., Onwudiwe, N., Deyo, R.A. and Jarvik, J.G. (2007) Thoracic and lumbar vertebroplasties performed in US Medicare enrollees, 2001–2005. Journal of the American Medical Association 298 (15): 1760–1762.
Guilhot, F. et al (2009) High rates of durable response are achieved with imatinib after treatment with interferon α plus cytarabine: Results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica 94 (12): 1669–1675.
Hennekens, C.H. and DeMets, D. (2009) The need for large-scale randomized evidence without undue emphasis on small trials, meta-analyses, or subgroup analyses. Journal of the American Medical Association 302 (21): 2361–2362.
Ioannidis, J.P.A. (2008) Effectiveness of antidepressants: An evidence myth constructed from a thousand randomized trials? Philosophy, Ethics, and Humanities in Medicine 3 (1): 14.
Jacobson, M., O'Malley, A.J., Earle, C.C., Pakes, J., Gaccione, P. and Newhouse, J.P. (2006) Does reimbursement influence chemotherapy treatment for cancer patients? Health Affairs 25 (2): 437–444.
Jensen, M.E., Evans, A.J., Mathis, J.M., Kallmes, D.F., Cloft, H.J. and Dion, J.E. (1997) Percutaneous polymethylmethacrylate vertebroplasty in the treatment of osteoporotic vertebral body compression fractures: Technical aspects. American Journal of Neuroradiology 18 (10): 1897–1904.
Kallmes, D.F. et al (2009) A randomized trial of vertebroplasty for osteoporotic spinal fractures. New England Journal of Medicine 361 (6): 569–579.
Kjaergard, L.L. and Als-Nielsen, B. (2002) Association between competing interests and authors’ conclusions: Epidemiological study of randomised clinical trials published in the BMJ. British Medical Journal 325 (7358): 249–253.
Kolata, G. (2005) Spinal cement draws patients and questions. The New York Times, 28 August.
LeLorier, J., Grégoire, G., Benhaddad, A., Lapierre, J. and Derderian, F.N. (1997) Discrepancies between meta-analyses and subsequent large randomized, controlled trials. New England Journal of Medicine 337 (8): 536–542.
Lievens, Y. and Van den Bogaert, W. (2005) Proton beam therapy: Too expensive to become true? Radiotherapy and Oncology 75 (2): 131–133.
Macklin, R. (1999) The ethical problems with sham surgery in clinical research. New England Journal of Medicine 341 (13): 992–996.
Meldrum, M. (2000) A brief history of the randomized controlled trial from oranges and lemons to the gold standard. Hematology/Oncology Clinics of North America 14 (4): 745–760.
Miller, F.G. and Joffe, S. (2011) Equipoise and the dilemma of randomized clinical trials. New England Journal of Medicine 364 (5): 476–480.
Miller, M., Boyer, M.J., Butow, P.N., Gattellari, M., Dunn, S.M. and Childs, A. (1998) The use of unproven methods of treatment by cancer patients: Frequency, expectations and cost. Supportive Care in Cancer 6 (4): 337–347.
Moseley, J.B. et al (2002) A controlled trial of arthroscopic surgery for osteoarthritis of the knee. New England Journal of Medicine 347 (2): 81–88.
Overgaard, M. et al (1997) Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. New England Journal of Medicine 337 (14): 949–955.
Prasad, V. (2010) Beyond storytelling in medicine: An encounter based curriculum. Academic Medicine 85 (5): 794–798.
Prasad, V., Gall, V. and Cifu, A. (2011) The frequency of medical reversal. Archives of Internal Medicine 171 (18): 1675–1676.
Rosamond, W. et al (2007) Heart disease and stroke statistics, 2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (5): e69–e171.
Schröder, F.H. et al (2009) Screening and prostate-cancer mortality in a randomized European study. New England Journal of Medicine 360 (13): 1320–1328.
Serruys, P.W. et al (2009) Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. New England Journal of Medicine 360 (10): 961–972.
Shafrin, J. (2010) Operating on commission: Analyzing how physician financial incentives affect surgery rates. Health Economics 19 (5): 562–580.
Shahinian, V.B., Kuo, Y.F., Freeman, J.L. and Goodwin, J.S. (2007) Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology 25 (34): 5359–5365.
Smith, G.C.S. and Pell, J.P. (2003) Parachute use to prevent death and major trauma related to gravitational challenge: Systematic review of randomised controlled trials. British Journal of Medicine 327 (7429): 1459–1461.
Smith, S. (2004) Older breast cancer patients are urged to avoid radiation. Boston Globe, 2 September.
Studer, M., Briel, M., Leimenstoll, B., Glass, T.R. and Bucher, H.C. (2005) Effect of different antilipidemic agents and diets on mortality: A systematic review. Archive of Internal Medicine 165 (7): 725–730.
Tatsioni, A., Bonitsis, N.G. and Ioannidis, J.P.A. (2007) Persistence of contradicted claims in the literature. Journal of the American Medical Association 298 (21): 2517–2526.
Taylor, A.J. et al (2009) Extended-release niacin or ezetimibe and carotid intima-media thickness. New England Journal of Medicine 361 (22): 2113–2122.
Tomlinson, G. and Detsky, A.S. (2010) Composite end points in randomized trials: There is no free lunch. Journal of the American Medical Association 303 (3): 267–268.
Turner, J.A., Deyo, R.A., Loeser, J.D., Von Korff, M. and Fordyce, W.E. (1994) The importance of placebo effects in pain treatment and research. Journal of the American Medical Association 271 (20): 1609–1614.
Vons, C. et al (2011) Amoxicillin plus clavulanic acid versus appendicectomy for treatment of acute uncomplicated appendicitis: An open-label, non-inferiority, randomised controlled trial. The Lancet 377 (9777): 1573–1579.
Writing Group for the Women's Health Initiative Investigators. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association 288 (3): 321–333.
Woolf, S.H. (2010) The 2009 Breast Cancer Screening Recommendations of the US Preventive Services Task Force. Journal of the American Medical Association 303 (2): 162–163.
Worrall, J. (2007) Why there's no cause to randomize. British Journal for the Philosophy of Science 58 (3): 451–488.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Prasad, V., Cifu, A. A medical burden of proof: Towards a new ethic. BioSocieties 7, 72–87 (2012). https://doi.org/10.1057/biosoc.2011.25
Published:
Issue Date:
DOI: https://doi.org/10.1057/biosoc.2011.25